Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Monday, 27 March 2023

Tuesday, 28 March 2023

18:30-19:30 CEST

13:00-14:10 CEST

Programme

Welcome and introduction, Scientific background and context
Ana Oaknin, Vall d'Hebron University Hospital, Barcelona, Spain

Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Mansoor Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark

Critical analysis and perspectives
Ilaria Colombo, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland

AACR Expert Commentary
Elise C. Kohn, National Cancer Institute, Bethesda, MD, USA

Discussion and Q&A (i)
Faculty and online audience

Programme

Virtual Plenary Expert Insights: Webcast of 27 March presentations, Discussion and Q&A (ii)
Faculty and online audience

Chair: David SP Tan, NUHS - National University Health System, Singapore

Mansoor Mirza, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark

Ilaria Colombo, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland

Kenichi Harano, National Cancer Center Hospital East, Kashiwa, Japan

Byoung-Gie Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Clare Scott, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Airs on 27 March 2023 at 18:30 CEST

Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

You may also be interested in...